(Circulation. 1999;99:1747-1752.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Chronic Endothelin Receptor Antagonism Preserves Coronary Endothelial Function in Experimental Hypercholesterolemia
From the Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn.
Correspondence to Amir Lerman, MD, Department of Internal Medicine and Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail lerman.amir{at}mayo.edu
Background—Endothelin-1 (ET-1) is an endothelium-derived peptide that constricts coronary vessels through stimulation of the ET-A and ET-B receptors. Experimental porcine hypercholesterolemia is associated with impaired coronary endothelial function and elevated ET-1 concentrations. This study was designed to test the hypothesis that chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.
Methods and Results—Acetylcholine (10-6 to 10-4 mol/L) was serially infused into the left anterior descending coronary artery in pigs at baseline and after 12 weeks of a high-cholesterol diet. In the interim, the animals were randomized to 3 groups: Group 1 received no therapy, group 2 received 3 mg/kg per day RO 48-5695, a combined ET-A/ET-B receptor antagonist, and group 3 received 4 mg/kg per day ABT-627, a selective ET-A receptor antagonist. Percent change in coronary artery diameter, coronary blood flow, and coronary vascular resistance were calculated on the basis of quantitative coronary angiography and intracoronary Doppler. At 12 weeks, total cholesterol was significantly and similarly increased in all groups. Chronic endothelin receptor antagonism significantly increased coronary blood flow in response to acetylcholine at 12 weeks (group 1: -41.6%±10.7%, group 2: -4.7%±11.9%, group 3: 11.4%±7.4%).
Conclusions—Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. This study supports the role for ET-1 in the pathogenesis of endothelial function. Moreover, endothelin receptor antagonists may have a therapeutic role by maintaining coronary endothelial function in pathophysiological states.
Key Words: endothelin • receptors • vessels • endothelium-derived factors • hypercholesterolemia • vasculature
This article has been cited by other articles:
 |
|
 |
|
  N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Ritman and A. Lerman The dynamic vasa vasorum Cardiovasc Res, September 1, 2007; 75(4): 649 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gossl and A. Lerman Endothelin: Beyond a Vasoconstrictor Circulation, March 7, 2006; 113(9): 1156 - 1158. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Boak, A. M. Dart, S. J. Duffy, and J. P. F. Chin-Dusting Responses to neither exogenous nor endogenous endothelin-1 are altered in patients with hypercholesterolemia J. Lipid Res., December 1, 2005; 46(12): 2667 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E Pyke and M. E Tschakovsky The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function J. Physiol., October 15, 2005; 568(2): 357 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Thirunavukkarasu, Y Yang, V M Subbotin, S A K Harvey, J Fung, and C R Gandhi Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats Gut, July 1, 2004; 53(7): 1010 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gottlieb The neurohormonal paradigm:have we gone too far? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1458 - 1459. [Full Text] [PDF]
|
|
|
|
 |
|
 P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, P. J. Best, E. L. Ritman, D. R. Holmes Jr, L. O. Lerman, and A. Lerman Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1555 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V Agapitov and W. G Haynes Role of endothelin in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
|
|
L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wentzel, R. Krams, J. C. H. Schuurbiers, J. A. Oomen, J. Kloet, W. J. van der Giessen, P. W. Serruys, and C. J. Slager Relationship Between Neointimal Thickness and Shear Stress After Wallstent Implantation in Human Coronary Arteries Circulation, April 3, 2001; 103(13): 1740 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Taner, S. R. Severson, P. J. M. Best, A. Lerman, and V. M. Miller Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia J Appl Physiol, March 1, 2001; 90(3): 816 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mohlenkamp, L. O. Lerman, A. Lerman, T. R. Behrenbeck, Z. S. Katusic, P. F. Sheedy II, and E. L. Ritman Minimally Invasive Evaluation of Coronary Microvascular Function by Electron Beam Computed Tomography Circulation, November 7, 2000; 102(19): 2411 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cardillo, C. M. Kilcoyne, R. O. Cannon III, and J. A. Panza Increased activity of endogenous endothelin in patients with hypercholesterolemia J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Babaei, P. Picard, A. Ravandi, J. C. Monge, T. C. Lee, P. Cernacek, and D. J. Stewart Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation Cardiovasc Res, October 1, 2000; 48(1): 158 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser, R. Merten, S. Spiekermann, K. Buttner, H. Drexler, and B. Hornig Vascular Extracellular Superoxide Dismutase Activity in Patients With Coronary Artery Disease : Relation to Endothelium-Dependent Vasodilation Circulation, May 16, 2000; 101(19): 2264 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.J. Halcox, K. R.A. Nour, G. Zalos, and A. A. Quyyumi Coronary Vasodilation and Improvement in Endothelial Dysfunction With Endothelin ETA Receptor Blockade Circ. Res., November 23, 2001; 89(11): 969 - 976. [Abstract] [Full Text] [PDF]
|
|